ESSEX BIO-TECH Executes Further Share Buyback; 10,000 Shares Acquired at HKD 2.71 Each

Bulletin Express06-29

Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD 27,100.

Following the transaction: • Issued shares (excluding treasury shares) decreased to 566.27 million, down 0.00177%. • Treasury shares rose to 0.73 million. • Total issued shares remained at 567.01 million.

The buyback forms part of a mandate approved on 26 May 2026 authorising the company to repurchase up to 56.70 million shares. To date, 0.73 million shares—equivalent to 0.13% of the share base at mandate approval—have been repurchased, leaving capacity for a further 55.97 million shares.

In line with Hong Kong listing rules, Essex Bio-Tech is subject to a 30-day moratorium—through 29 July 2026—on issuing new shares or disposing of treasury shares following this repurchase. The company confirmed that the transaction complied with all regulatory requirements and its board authorisation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124235840?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124235840","market":"hk","top_or_hot":-1,"title":"ESSEX BIO-TECH Executes Further Share Buyback; 10,000 Shares Acquired at HKD 2.71 Each","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD 27,100.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) decreased to 566.27 million, down 0.00177%.  \n• Treasury shares rose to 0.73 million.  \n• Total issued shares remained at 567.01 million.</p>\n<p>The buyback forms part of a mandate approved on 26 May 2026 authorising the company to repurchase up to 56.70 million shares. To date, 0.73 million shares—equivalent to 0.13% of the share base at mandate approval—have been repurchased, leaving capacity for a further 55.97 million shares.</p>\n<p>In line with Hong Kong listing rules, Essex Bio-Tech is subject to a 30-day moratorium—through 29 July 2026—on issuing new shares or disposing of treasury shares following this repurchase. The company confirmed that the transaction complied with all regulatory requirements and its board authorisation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ESSEX BIO-TECH Executes Further Share Buyback; 10,000 Shares Acquired at HKD 2.71 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nESSEX BIO-TECH Executes Further Share Buyback; 10,000 Shares Acquired at HKD 2.71 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-29 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD 27,100.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) decreased to 566.27 million, down 0.00177%.  \n• Treasury shares rose to 0.73 million.  \n• Total issued shares remained at 567.01 million.</p>\n<p>The buyback forms part of a mandate approved on 26 May 2026 authorising the company to repurchase up to 56.70 million shares. To date, 0.73 million shares—equivalent to 0.13% of the share base at mandate approval—have been repurchased, leaving capacity for a further 55.97 million shares.</p>\n<p>In line with Hong Kong listing rules, Essex Bio-Tech is subject to a 30-day moratorium—through 29 July 2026—on issuing new shares or disposing of treasury shares following this repurchase. The company confirmed that the transaction complied with all regulatory requirements and its board authorisation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1124235840","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124235840","pubTimestamp":1782723914,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"埃塞克斯生物技术公司执行进一步的股票回购；以每股2.71港元收购10,000股股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited disclosed that on 29 June 2026 it repurchased 10,000 ordinary shares on the Hong Kong Stock Exchange at a price of HKD 2.71 per share, for a total consideration of HKD 27,100.\nFollowing the transaction:\n• Issued shares (excluding treasury shares) decreased to 566.27 million, down 0.00177%.  \n• Treasury shares rose to 0.73 million.  \n• Total issued shares remained at 567.01 million.\nThe buyback forms part of a mandate approved on 26 May 2026 authorising the company to repurchase up to 56.70 million shares. To date, 0.73 million shares—equivalent to 0.13% of the share base at mandate approval—have been repurchased, leaving capacity for a further 55.97 million shares.\nIn line with Hong Kong listing rules, Essex Bio-Tech is subject to a 30-day moratorium—through 29 July 2026—on issuing new shares or disposing of treasury shares following this repurchase. The company confirmed that the transaction complied with all regulatory requirements and its board authorisation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124235840","isCrawlerRequest":true}